1,760 Shares of AbbVie Inc. $ABBV Acquired by MFG Investments LLC

MFG Investments LLC bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 1,760 shares of the company’s stock, valued at approximately $461,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Third View Private Wealth LLC boosted its position in AbbVie by 9.2% in the 3rd quarter. Third View Private Wealth LLC now owns 4,694 shares of the company’s stock valued at $1,228,000 after buying an additional 394 shares during the last quarter. Provenance Wealth Advisors LLC grew its stake in shares of AbbVie by 697.6% during the third quarter. Provenance Wealth Advisors LLC now owns 12,482 shares of the company’s stock valued at $3,265,000 after acquiring an additional 10,917 shares in the last quarter. One Day In July LLC increased its position in shares of AbbVie by 6.9% during the third quarter. One Day In July LLC now owns 3,359 shares of the company’s stock worth $879,000 after acquiring an additional 216 shares during the last quarter. Hughes Financial Services LLC increased its position in shares of AbbVie by 9.9% during the third quarter. Hughes Financial Services LLC now owns 719 shares of the company’s stock worth $188,000 after acquiring an additional 65 shares during the last quarter. Finally, Lyell Wealth Management LP lifted its stake in shares of AbbVie by 6.6% in the third quarter. Lyell Wealth Management LP now owns 3,859 shares of the company’s stock worth $1,009,000 after acquiring an additional 240 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of ABBV opened at $285.88 on Wednesday. The business’s fifty day moving average price is $270.23 and its 200 day moving average price is $237.89. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $298.74. The stock has a market capitalization of $505.09 billion, a PE ratio of 49.20, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the previous year, the firm earned $1.86 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 14.00 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on ABBV shares. Rothschild & Co Redburn increased their price target on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Oppenheimer lifted their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Guggenheim lifted their price objective on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday. BMO Capital Markets upped their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $296.88.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.